We seek to deliver therapeutic, diagnostic and production benefits in areas as diverse as cancer, immunology, public health and personalised treatment.

Our successful research areas demonstrate our dedication to advancing microbiome research and finding innovative solutions for different health conditions.

At MagIC, we are committed to driving groundbreaking discoveries that lead to personalized healthcare interventions and improved patient outcomes.

MOZAIC™

IBD-SMART™

Stool MicrobiAl BiomarkeR Test to aid diagnosis of Inflammatory

Metagenomics

Multiple Diseases Test

One Stool Test for Multi-Disease Early

MetaGenie™

Stool Test for Early Diagnosis of Autism Spectrum Disorder

Long COVID Gut Microbiome Risk Test

GenieBiome is established by a team of internationally renowned professors of medicine and clinician-scientists from The Chinese University of Hong Kong. They are among the global top echelon of researchers in the field of gut microbiome with strong academic standing and novel technologies.

90% of us are dominated by microbes in our bodies. GenieBiome pioneers the use of novel microbes as diagnostic markers and potential remedies for different diseases. With an exploding body of global research indicating that the gut microbiome plays a central role in health and disease, GenieBiome has rapidly positioned itself to be a leading force in the development of new diagnostics and therapeutics based on the gut microbiome. It combines cutting-edge and disruptive technologies into a pipeline that enables the prediction of early cancers and debilitating chronic diseases.

Utilizing our unique in-house dataset and those from publicly available sources, we have identified novel microbes as reliable, non-invasive biomarkers and developed proprietary machine-learning algorithms that can accurately predict disease risk.

Our Center is keen to promote Hong Kong, if not, the Great Bay Area into a microbiome hub. We welcome collaboration for industry development and clinical translation by providing high-quality sequencing cooperation.

A Microbiome-Based Genomics Solution

Microbiota I-Center (MagIC) Limited has been in the forefront of gut microbiome research.

Extensive research collaborations and partnerships are made with numerous top-tier research institutions. These collaborations have gathered talents and expertise from diverse disciplines, opening up a wide angle of research directions in gut microbiome.

Over the years, we have published more than 500 peer-reviewed articles related to microbiome /GI research in high impact factor journals, such as Nature Medicine, Cell Host & Microbe, The Lancet Infectious Diseases, contributing to the advancements in genomics research.

With the comprehensive experience and talents, we have successfully developed our own Microbiome-based Genomics Solution with optimized processes and protocols to ensure the best possible scientific outcome.

Cutting-Edge Technologies

Equipped with high-throughput sequencing platforms, Illumina NextSeq 550 System and NovaSeq 6000 System to unlock the possibilities of scalable and flexible sequencing across a wide spectrum of applications, such as metagenomics, whole-genome sequencing, single-cell RNA sequencing, microarray scanning.

Automation technologies: Tecan Freedom EVO® 150, is adopted to streamline the workflows, reducing manual errors while increasing throughput and efficiency.

Quality Control and Assurance

Rigorous quality control measures have been implemented at every stage – from sample acquisition to data analysis, in accordance with the international standards to ensure the accuracy, reproducibility, repeatability and reliability of sequence data.

Comprehensive Bioinformatics Solutions Powered by
High-Performance Computing (HPC) Server

We offered a suite of bioinformatics tools and software that facilitate the analysis of metagenomics data. The pipelines and analysis workflows are tailored for microbiome datasets. Powered by our high-performance computing server and supported by a group of dedicated bioinformatic analysts, we are capable of analyzing hundreds of metagenomics data per month. We perform cutting-edge big data, multi-omics analyses and machine learning models and transform these data into clinical applications.

Anchor 1

INVITATION FOR EXPRESSION OF INTEREST (EOI) 1. Fungome and FMT (Closed) [Invitation for Expression of Interest – Deadline: 19 May 2023] 2. ASD Multi-kingdom (Closed) [Invitation for Expression of Interest – Deadline: 21 Aug 2023] 3. CD Bacterial Markers (Closed) [Invitation for Expression of Interest – Deadline: 19 Feb 2024] 4. UC Bacterial Markers (Closed) [Invitation for Expression of Interest – Deadline: 19 Feb 2024] 5. MAFLD Formula (Closed) [Invitation for Expression of Interest – Deadline: 18 Mar 2024] 6. SIM05 Adult Eczema (Closed) [Invitation for Expression of Interest – Deadline: 28 Mar 2024] 7. SCM06 Mood (Closed) [Invitation for Expression of Interest – Deadline: 28 Ma